<DOC>
	<DOCNO>NCT00104871</DOCNO>
	<brief_summary>This phase II trial study well bortezomib work treat patient metastatic thyroid cancer respond radioactive iodine therapy . Bortezomib may stop growth tumor cell block enzymes need cell growth</brief_summary>
	<brief_title>Bortezomib Treating Patients With Metastatic Thyroid Cancer That Did Not Respond Radioactive Iodine Therapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . Determine efficacy bortezomib , term tumor response rate , patient metastatic papillary follicular thyroid cancer unresponsive prior radioiodine therapy . SECONDARY OBJECTIVE : I . Determine clinical activity drug , term progression-free survival , patient treat drug . OUTLINE : This open-label , multicenter study . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Treatment repeat every 21 day least 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma , Follicular</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>The Eastern Cooperative Oncology Group ( ECOG ) 02 OR Karnofsky 60100 % Platelet count &gt; = 100,000/mm^3 Absolute neutrophil count &gt; = 1,500/mm^3 White Blood Count ( WBC ) &gt; = 3,000/mm^3 Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) = &lt; 2.5 time upper limit normal Bilirubin normal No symptomatic congestive heart failure Creatinine normal OR creatinine clearance &gt; = 60 mL/min No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No ongoing active infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness At least 4 week since prior chemotherapy No 2 prior chemotherapy regimen At least 6 month since prior external beam radiotherapy locoregional disease thyroid bed cervical upper mediastinal lymph node ( dose = &lt; 6,000 cGy ) At least 6 month since prior radioiodine therapy No prior external radiotherapy measure tumor Prior thyroidectomy allow No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent anticancer therapy Unresponsive prior radioiodine therapy Histologically confirm differentiate thyroid cancerpapillary follicular type , include , limited , follow variant : hurthle cell ( oxyphilic ) , insular , columnar cell , tall cell Metastatic disease At least 1 unidimensionally measurable lesion &gt; = 20 mm conventional technique OR &gt; = 10 mm spiral CT scan No prior radiotherapy measurable lesion No radioiodine uptake measure metastatic tumor radioiodine scan ( Note : Must &gt; = 1 radioiodine scan since last radioiodine treatment ) No know brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>National Thyroid Cancer Treatment Cooperative Study Group</keyword>
	<keyword>NTCTCSG</keyword>
	<keyword>bortezomib</keyword>
	<keyword>velcade</keyword>
	<keyword>metastatic differentiate thyroid carcinoma</keyword>
	<keyword>Differentiated thyroid carcinoma</keyword>
	<keyword>follicular epithelial thyroid cell</keyword>
	<keyword>papillary</keyword>
	<keyword>oxyphilic cell</keyword>
	<keyword>Hurthle cell</keyword>
	<keyword>insular cell</keyword>
	<keyword>columnar cell</keyword>
	<keyword>tall cell</keyword>
</DOC>